Phase 2Heart FailureRecruiting
HFpEF — PF-07328948
HFpEF (Metabolic Therapy)
About this study
Metabolic-pathway therapy under investigation for symptomatic improvement in heart failure with preserved ejection fraction.
Sponsor: Pfizer
Key eligibility
- Adults with confirmed HFpEF
- BMI ≥ 27
- Stable cardiovascular medications ≥ 30 days
Eligibility above is a summary. Final qualification is determined by the study protocol and a screening visit with our team.
What participation involves
Most studies follow the same general flow: a phone pre-screen, an in-person screening visit, informed consent, baseline testing, the treatment phase, and follow-up visits. Study-related care is provided at no cost. You may withdraw at any time, for any reason.
Note
This page is a plain-language overview. For the official, definitive protocol summary, please refer to ClinicalTrials.gov or speak with our coordinator.